Novo Nordisk A/S (NVO)

業務介紹

諾和諾德公司(Novo Nordisk A/S)是一家醫療保健公司,從事藥品的研究、開發、製造和全球銷售。該公司分為兩個業務部門:糖尿病和肥胖症護理,以及生物製藥。糖尿病和肥胖症護理部門提供胰島素、GLP-1及相關給藥系統、口服降糖藥品、肥胖症和其他慢性疾病的產品。生物製藥部門提供血友病、生長障礙和激素替代療法的產品。該公司與吉利德科學公司(Gilead Sciences, Inc.)有合作協議,並與Lumen Bioscience, Inc.有研究合作,探索用於心臟代謝疾病的口服生物製品遞送策略。該公司成立於1923年,總部位於丹麥的巴格斯維爾德。



Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

公司網址

https://www.novonordisk.com